Anbio Biotechnology (NNNN) vs Pro-Dex (PDEX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pro-Dex (PDEX) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 79.1% versus a loss of 85.1%. Anbio Biotechnology is the larger company by market cap ($202.8 million vs $201.1 million), about 1.0 times the size. On valuation, Pro-Dex trades at a lower trailing P/E (15.1x vs 30.8x for Anbio Biotechnology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | PDEX |
|---|---|---|
| Share price | $4.62 | $62.21 |
| Market cap | $202.78M | $201.14M |
| 1-day change | -5.71% | -0.94% |
| YTD return | -84.64% | +61.67% |
| 1-year return | -85.09% | +79.07% |
| 5-year return | — | +141.97% |
| P/E ratio (TTM) | 30.80 | 15.10 |
| Forward P/E | — | 18.51 |
| EPS (TTM) | $0.15 | $4.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $77.00 |
| 52-week low | $4.55 | $23.47 |
| Distance from 52-week high | -89.67% | -19.21% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +18.95% |
| Average volume | 146.84K | 81.57K |
| Shares outstanding | 43.89M | 3.23M |
| Employees | 27 | 201 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDEX has outperformed NNNN by 164.2 percentage points over the past year.
- Anbio Biotechnology trades at a higher earnings multiple (30.8x vs 15.1x trailing P/E).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Pro-Dex
PDEX stock →Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide.
Health Care · Medical/Dental Instruments · 201 employees
NNNN vs PDEX FAQ
Which is bigger, Anbio Biotechnology or Pro-Dex?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $202.78M compared with $201.14M for Pro-Dex (PDEX).
Which stock has performed better over the past year, NNNN or PDEX?
PDEX returned +79.07% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NNNN or PDEX?
PDEX has the lower trailing P/E at 15.1, versus 30.8 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Anbio Biotechnology and Pro-Dex in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Medical/Dental Instruments for Pro-Dex.